CH
NBIX icon

Cromwell Holdings’s Neurocrine Biosciences NBIX Stock Holding History

Cromwell Holdings’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.55K Buy
27
+10
+59% +$1.48K ﹤0.01% 680
2026
Q1 		$2.24K Hold
17
– – ﹤0.01% 694
2025
Q4 		$2.41K Hold
17
– – ﹤0.01% 665
2025
Q3 		$2.39K Hold
17
– – ﹤0.01% 676
2025
Q2 		$2.14K Buy
17
+10
+143% +$1.15K ﹤0.01% 676
2025
Q1 		$774 Buy
+7
New +$887 ﹤0.01% 688

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Cromwell Holdings's NBIX Position: Q2 2026 in Review

Cromwell Holdings increased its Neurocrine Biosciences (NBIX) stake by 59% in Q2 2026, buying an estimated $1.48K and bringing the position to 27 shares worth $4.55K. The position accounts for ﹤0.01% of the portfolio, ranked #680.

Cromwell Holdings first reported a position in NBIX in Q1 2025 and has held it in 6 quarters since. 775 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Cromwell Holdings held 27 shares of Neurocrine Biosciences worth $4.55K as of Q2 2026.
  • Cromwell Holdings bought 10 Neurocrine Biosciences shares in Q2 2026, an estimated $1.48K.
  • Neurocrine Biosciences made up ﹤0.01% of Cromwell Holdings's portfolio in Q2 2026, its #680 holding.
  • Cromwell Holdings first reported a position in Neurocrine Biosciences in Q1 2025 and has held it in 6 quarters since.
  • 775 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Cromwell Holdings's 13F filing for Q2 2026, filed 14 Jul 2026.